NSCLC STAGE IV
Clinical trials for NSCLC STAGE IV explained in plain language.
Never miss a new study
Get alerted when new NSCLC STAGE IV trials appear
Sign up with your email to follow new studies for NSCLC STAGE IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat lung cancer
Disease control CompletedThis phase 2 trial tested a combination of chemotherapy (carboplatin or cisplatin plus pemetrexed) and immunotherapy (atezolizumab, with or without bevacizumab) in 150 people with advanced non-squamous non-small cell lung cancer that has EGFR, ALK, or ROS1 mutations and has progr…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Can zapping cancer spots delay lung cancer progression?
Disease control CompletedThis study tested whether a procedure called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows signs of remaining cancer (minimal residual disease, or MRD). 37 patients with stage IV NSCLC received LAT to all visib…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Promising combo tackles tough lung cancer
Disease control CompletedThis study tested a new two-drug combination (bemcentinib plus pembrolizumab) in 99 adults with advanced lung cancer that had already been treated. The goal was to see if the combination could shrink tumors or stop them from growing. Participants received both drugs by mouth or I…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: BerGenBio ASA • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New scan may reveal who will benefit from immunotherapy
Diagnosis CompletedThis study tested whether a new type of PET scan, which looks for a protein called PD-L1 on cancer cells, can predict how well patients with advanced lung cancer will respond to the immunotherapy drug nivolumab. Eighty patients received the scan before starting treatment. Researc…
Matched conditions: NSCLC STAGE IV
Phase: NA • Sponsor: The Netherlands Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC